Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Diagens Biotechnology Co's EBIT per Share for the
three
months ended in Jun. 2026 was HK$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-0.81.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Hangzhou Diagens Biotechnology Co's EBIT per Share or its related term are showing as below:
HKSE:02526's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Hangzhou Diagens Biotechnology Co (HKSE:02526) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Hangzhou Diagens Biotechnology Co EBIT per Share Related Terms
Hangzhou Diagens Biotechnology Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Diagens Biotechnology Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-0.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a EBIT per Share of HK$-0.81 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. According to the industry distribution chart, Hangzhou Diagens Biotechnology Co ranks #999999 out of 683 companies in the Medical Devices & Instruments industry.
Is Hangzhou Diagens Biotechnology Co's EBIT per Share too high?
Hangzhou Diagens Biotechnology Co's current EBIT per Share is HK$-0.81. Based on the distribution chart, Hangzhou Diagens Biotechnology Co ranks #999999 out of 683 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Diagens Biotechnology Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Diagens Biotechnology Co's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Diagens Biotechnology Co ranks #999999 out of 683 companies for EBIT per Share. This places Hangzhou Diagens Biotechnology Co in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Diagens Biotechnology Co's current EBIT per Share is HK$-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Diagens Biotechnology Co stock overvalued right now?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a current EBIT per Share of HK$-0.81. The current EBIT per Share is HK$-0.81. Hangzhou Diagens Biotechnology Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hangzhou Diagens Biotechnology Co (HKSE:02526), the current EBIT per Share is HK$-0.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
8GF Score
Get the complete analysis for HKSE:02526
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02526 has been successfully added to your 
